Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2011-08-02
2011-08-02
Angell, Jon E (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093700
Reexamination Certificate
active
07988959
ABSTRACT:
The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.
REFERENCES:
patent: 4485096 (1984-11-01), Bell
patent: 5292655 (1994-03-01), Wille
patent: 5536656 (1996-07-01), Kemp et al.
patent: 5658331 (1997-08-01), Della Valle et al.
patent: 5693332 (1997-12-01), Hansbrough
patent: 5968546 (1999-10-01), Baur et al.
patent: 5989837 (1999-11-01), Allen-Hoffmann et al.
patent: 6039760 (2000-03-01), Eisenberg
patent: 6458382 (2002-10-01), Herweijer et al.
patent: 6793918 (2004-09-01), Enholm
patent: 6838430 (2005-01-01), Arbeit
patent: 6846675 (2005-01-01), Conrad et al.
patent: 6849718 (2005-02-01), Kaelin et al.
patent: 7192605 (2007-03-01), Herweijer et al.
patent: 2001/0048917 (2001-12-01), Hoeffler et al.
patent: 2002/0187498 (2002-12-01), Comer
patent: 2003/0152562 (2003-08-01), Mitrani
patent: 2004/0190793 (2004-09-01), Rorvig
patent: 2005/0013807 (2005-01-01), Comer
patent: 2005/0079578 (2005-04-01), Centanni
patent: 2005/0186185 (2005-08-01), Conrad
International Search Report: ISR PCT/US2003/13327 Dated: Mar. 2, 2005.
Brown, et al., Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes during Wound HealingJ. Exp. Med 176:1375-9 (1992).
Boucamp et al., Normal Keratinization in a Spontaneously Immortalized Aneuploid Human Keratinocyte Cell Line J. Cell Boil. 106:761-771 (1998).
Carmeliet, et al., Abnormal Blood Vessel Development and Lethality in Embryos Lacking a Single VEGF Allele, Nature 380:435-9. (1996).
Del Rio et al, A Preclinical Model for the Analysis of Genetically Modified Human Skin In Vivo, Human Gene Therapy, 13:959-968, 2002.
Del Rio et al., Current Approaches and Perspectives in Human Keratinocyte-Based Gene Therapies, Gene Threapy, 11:S57-S63, 2004.
Ferrara, et al.,Heterozygous Embryonic Lethality Induced by Targeted Inactivation of the VEGF Gene, Nature 380:439-42. (1996).
Fong, et al., Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium, Nature 376:66-70 (1995).
Koblizek, et al., Angiopoietin-1 Induces Sprouting Angiogenesis in Vitro, Curr Biol. 8:529-32 (1998).
Larcher et al., A Cutaneous Gene Therapy Approach to hUlnan Leptin Deficiencies: Correction of the Murine ob/ob Phenotype Using Leptin-Targeted Keratinocyte Grafts, FASEB J., 15, 1529-1538, 2001.
Maisonpierre, et al., Angiopoietin-2. a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis , Science 277:55-60. (1997).
Nehls & Drenckhahn, A Novel, Microcarrier-Based in Vitro Assay for Rapid and Reliable Quantification of Three-Dimensional Cell Migration and Angiogenesis, Microvasc. Res. 50:311-22 (1995).
Rio, et al., Nonviral Transfer of Genes to Pig Primary Keratinocytes. Induction of Angiogenesis by Composite Grafts of Modified Keratinocytes Overexpressing VEGF Driven By a Keratin Promoter, Gene Therapy, 6:1734-1741 (1999).
Shalaby, et al., Failure of Blood-Island Formation and Vasculogenesis in Flk-I-Deficient Mice, Nature 376:62-66 (1995).
JP Notice of Reasons for Rejection; Dated: Jan. 25, 2010; JP Patent Application Serial No.: 2004-501554; Applicant: Stratatech Corporation.
Supp et al., “Enhanced Vascularization of Cultured Skin Substitutes Genetically Modified to Overexpress Vascular Endothelial Growth Factor,” J Invest Dermatol, 2000, 114(1):5-13.
Bruick, et al., “Building better vasculatrue,” Genes Dev, 2001, 15(19):2497-2502.
Boyce et al., J. Burn Care Rehab. 20(6):453-461 (1999).
Meana et al., Burns 24:621-30 (1998).
Allen-Hoffmann et al., J. Invest. Dermatol., 114(3): 444-455 (2000).
Olofsson, et al., Curr Opin Biotechnol 10:528-35. (1999).
Carmeliet, Nat Med 6:389-95. (2000).
Bellomo, et al., Circ Res 86:E29-35. (2000).
Ferrara and Henzel, Biochem Biophys Res Commun 161:851-8 (1989).
Ferrara, et al., Methods Enzymol 198:391-405. (1991).
Detmar, et al., J Invest Dermatol 105:44-50. (1995).
Houck, et al., Mol Endocrinol 5:1806-14. (1991).
Yancopoulos, et al., Nature 407:242-8. (2000).
Carmeliet, et al., Nature 380:435-9. (1996).
Ferrara, et al., Nature 380:439-42. (1996).
Maisonpierre, et al., Science 277:55-60. (1997).
Moller, et al., Mol Hum Reprod 7:65-72. (2001).
Brown, et al., J Exp Med 176:1375-9. (1992).
Detmar, et al., J Exp Med 180:1141-6. (1994).
Shweiki, et al., Proc Natl Acad Sci U S A 92:768-72. (1995).
Ballaun, et al., J Invest Dermatol 104:7-10. (1995).
Detmar, et al., J Invest Dermatol 108:263-8. (1997).
Frank, et al., J Biol Chem 270:12607-13. (1995).
Rivard, et al., Am J Pathol 154:355-63. (1999).
Larcher, et al., Oncogene 17:303-11. (1998).
Detmar, et al., J Invest Dermatol 111:1-6. (1998).
Davis, et al., Cell 87:1161-9. (1996).
Suri, et al., Cell 87:1171-80. (1996).
Gamble, et al., Circ Res 87:603-7. (2000).
Sato, et al., Nature 376:70-4. (1995).
Thurston, et al., Science 286:2511-4. (1999).
Suri, et al., Science 282:468-71. (1998).
Taub, et al., Plast Reconstr Surg 102:2033-9. (1998).
Tanaka, et al., J Thorac Cardiovasc Surg 120:720-8. (2000).
Vale, et al., Circulation 102:965-74 (2000).
Del Rio, et al., Gene Therapy 6:1734-1741 (1999).
Huang, et al., J. Biol. Chem., 271, 32253-32259 (1996).
Kallio, et al., Proc. Natl. Acad. Sci. USA, 94, 5667-5672 (1997).
Schroeder and Neagle, J. Biomol. Screening 1:75-80 [1996].
Myers et al., A. J. Surg. 170(1):75-83 (1995.
Wang, et al., Proc Natl Acad Sci U S A 91:8180-4. (1994).
Wang, et al., Gene Ther 4:432-41. (1997).
Gerdes, et al., J Immunol 133:1710-5. (1984).
Auger et al., In Vitro Cell. Dev. Biol.—Animal 36:96-103.
Asbill et al., Pharm. Research 17(9): 1092-97 (2000).
Baden, In Vitro Cell. Dev. Biol. 23(3):205-213 (1987).
Eriksson and Alitalo, Curr Top Microbiol Immunol 237:41-57 (1999).
Persico, et al., Curr Top Microbiol Immunol 237:31-40. (1999).
Senger, et al., Science 219:983-5. (1983).
Papapetropoulos, et al., Lab Invest 79:213-23. (1999).
O'Brien and Simari, Mayo Clin Proc 75:831-4. (2000).
Baumgartner, Curr Cardiol Rep 2:24-8. (2000).
Lopez, et al., Exp Cell Res 210:145-53. (1994).
Clontech (Jul. 1996 CLONTECHtechniques, [online], [retrieved on May 4, 2005] Retrieved from the Clontech using Internet <http://www.clontech.com/clonetech/archive/JUL96UPD/index.shtml>).
Allen-Hoffmann B. Lynn
Comer Allen R.
Angell Jon E
Casimir Jones SC
Stratatech Corporation
LandOfFree
Method of treatment using organotypically cultured skin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment using organotypically cultured skin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment using organotypically cultured skin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745313